12/3/2012

Marina Biotech granted Tekmira Pharmaceuticals nonexclusive global rights to use its Unlocked Nucleobase Analog RNAi payload technology to develop RNAi drugs. The technology can help enhance the stability and reduce the undesired effects of RNAi drugs, the firms said. The deal entitles Marina to an upfront payment plus milestone fees and royalties on products arising from the collaboration.

Related Summaries